Liver Function Tests (LFT)
Liver Function Tests (LFT)
Longitudinal Data
| Date | T.Bili (mg/dL) | D.Bili (mg/dL) | ALT (U/L) | AST (U/L) | ALP (U/L) | T.Protein (g/dL) | Albumin (g/dL) | Globulin (g/dL) | Flag | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-06 | 0.3 | 0.1 | 19 | 19 | 73 | 7.2 | 4.4 | 2.86 | N (all normal) | raw/labs/2026-06-07_Ishamma_T_M_1.pdf |
| 2026-04-06 | 0.2 | 0.1 | 11 | 15 | 63 | 7.3 | 4.4 | 2.89 | N (all normal) | Ishamma T M.pdf |
| 2026-03-02 | 0.3 | 0.2 | 11 | 16 | 60 | — | — | — | N (all normal) | Ishamma T M 4.pdf |
| 2026-01-19 | 0.4 | 0.2 | 14 | 19 | 77 | 7.6 | 4.4 | 3.2 | N (all normal) | Ishamma T M 1 7.pdf |
Reference Ranges (KIMS Health):
- Bilirubin Total: <1.2 mg/dL
- Bilirubin Direct: 0–0.30 mg/dL
- ALT: 10–35 U/L
- AST: 10–35 U/L
- ALP: 35–104 U/L
- Total Protein: 6.80–8.70 g/dL
- Albumin: 3.50–5.20 g/dL
- Globulin: 2.20–3.60 g/dL
Trend Analysis
Four LFT panels available — all entirely normal.
- 2026-01-19 (Cycle 2 start, "Hepatic Panel 2"): Full panel including protein fractions. All values well within reference range. Albumin 4.4 g/dL indicates good synthetic liver function and nutritional status. Bill No: L005244326.
- 2026-03-02 (Cycle 3 start, "Hepatic Panel 1"): Abbreviated panel (bilirubin, transaminases, ALP — no protein fractions). All values normal. ALP notably decreased (77 → 60) which is reassuring. Authorized by Greeshma M Nair MSc Medical Biochemistry. Bill No: L016926626.
- 2026-04-06 (Cycle 4+ start, "Hepatic Panel 2"): Full panel with protein fractions. All values normal. TBil improved to 0.2, ALT/AST stable (11/15). ALP 63 (slight increase from 60 but well within range). TP 7.3, Alb 4.4 (unchanged), Glob 2.89. Bill No: L025985226.
- 2026-06-06 ("Hepatic Panel 2"): Full panel with protein fractions. All values normal. TBil 0.3, DBil 0.1, ALT 19 (slightly increased from 11 but still well within normal 10-35), AST 19 (slightly increased from 15, also normal). ALP 73 (increased from 63, still normal 35-104). TP 7.2, Alb 4.4 (stable), Glob 2.86. Bill No: L042743426. Authorized 12:21-12:26 PM.
Clinical significance: This patient is on three potentially hepatotoxic medications: Venetoclax, Azacitidine, and Posaconazole (strong CYP3A4 inhibitor). The fact that LFTs remain normal after 4+ months of therapy is very reassuring — no evidence of drug-induced liver injury (DILI).
[!info] LFT Gap Resolved
This refine pass discovered LFTs that were previously flagged as a critical gap. The Overview statement "LFTs: All normal (no hepatotoxicity)" is now verified with two source documents.
Related Pages
- Venetoclax — Hepatotoxic medication, LFT monitoring required
- Azacitidine — Hepatotoxic medication
- Posaconazole — Strong CYP3A4 inhibitor, hepatotoxic
- Calcium — Drawn on same panels
- Creatinine — Drawn on same panels
Sources: raw/labs/Ishamma T M 1 7.pdf, raw/labs/Ishamma T M 4.pdf